ITI Inc (NASDAQ:ITCI), a Company on the leading edge of transforming vaccines, announced the preliminary results of a Phase IB study of JRC-LAMP-vax™, a novel immunotherapy designed to treat individuals with allergy to Japanese red cedar (“JRC”). The Company is pleased to report that the Phase IB has met and maintained all primary safety and secondary immunological end points that were observed at the conclusion … Continue reading Drug Manufacturers Most Volatile: ITI Inc (NASDAQ:ITCI), TherapeuticsMD Inc (NYSEMKT:TXMD), KaloBios Pharmaceuticals (NASDAQ:KBIO), Auspex Pharmaceuticals Inc (NASDAQ:ASPX)